ArticleCureus2025
Fractionated Stereotactic Radiotherapy for Brain Metastases: A Moroccan Multicenter Experience.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStereotactic radiotherapy is currently an essential therapeutic tool in the treatment of brain metastases. The aim of our study was to report a multicenter Moroccan experience on stereotactic radiotherapy using linear accelerators in the treatment of brain metastases. MATERIAL AND
methodsWe conducted a multicenter retrospective study that included 130 patients treated at five centers in Morocco for brain metastases during the period between January 2021 and December 2024. All patients received fractionated stereotactic radiotherapy delivered by a linear accelerator. Statistical analysis of the data was performed using Jamovi version 2.3.
resultsWe collected 130 patients with 248 treated brain metastases. The mean age was 58.4 (24-88) with a female predominance (59.2%). The most common primary tumor was lung cancer (77 patients, 59.2%), followed by breast cancer (29 patients, 22.3%) and colorectal cancer (eight patients, 6.1%). Adenocarcinoma was the predominant histological type (104 patients, 73.5%), followed by squamous cell carcinoma (11 patients, 8.5%). The majority of patients had fewer than three metastases. The mean tumor size was 23.8 mm, and the median volume was 8 cc (0.05-89). The two most prescribed irradiation regimens were 3 × 9 Gy and 5 × 6 Gy (37 cases or 28%). The lowest biologically effective dose with α/β = 10 (BED10) was 35.7 in five patients (4%), with a mean BED10 of 51. Follow-up data were available for 59 patients. After a median follow-up of 10.9 months (2-36 months) since the onset of brain metastases, overall survival at 24 months was 48.2%.
conclusionStereotactic radiotherapy remains an effective treatment for local control of brain metastases. However, further studies are needed to homogenize practices and establish guidelines and procedures to improve long-term results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.